We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Nektar Therapeutics (NKTR - Free Report) shares soared 51.1% in the last trading session to close at $56. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4.4% loss over the past four weeks.
The stock rallied after the company announced positive data from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study evaluating rezpeg in patients with moderate-to-severe atopic dermatitis (AD). Data from the same showed that treatment with rezpeg led to durable and new responses across key disease measurements with both monthly and quarterly dosing. The safety profile of rezpeg seen in maintenance was similar to that seen in the induction phase of the study.
This biopharmaceutical company is expected to post quarterly loss of $2.69 per share in its upcoming report, which represents a year-over-year change of -19.6%. Revenues are expected to be $9.06 million, down 68.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Nektar, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NKTR going forward to see if this recent jump can turn into more strength down the road.
Nektar is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Merck KGaA (MKKGY - Free Report) , finished the last trading session 1.2% higher at $29.88. MKKGY has returned -3.8% over the past month.
Merck KGaA's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.47. Compared to the company's year-ago EPS, this represents a change of -13%. Merck KGaA currently boasts a Zacks Rank of #2 (Buy).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock?
Nektar Therapeutics (NKTR - Free Report) shares soared 51.1% in the last trading session to close at $56. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4.4% loss over the past four weeks.
The stock rallied after the company announced positive data from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study evaluating rezpeg in patients with moderate-to-severe atopic dermatitis (AD). Data from the same showed that treatment with rezpeg led to durable and new responses across key disease measurements with both monthly and quarterly dosing. The safety profile of rezpeg seen in maintenance was similar to that seen in the induction phase of the study.
This biopharmaceutical company is expected to post quarterly loss of $2.69 per share in its upcoming report, which represents a year-over-year change of -19.6%. Revenues are expected to be $9.06 million, down 68.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Nektar, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NKTR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Nektar is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Merck KGaA (MKKGY - Free Report) , finished the last trading session 1.2% higher at $29.88. MKKGY has returned -3.8% over the past month.
Merck KGaA's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.47. Compared to the company's year-ago EPS, this represents a change of -13%. Merck KGaA currently boasts a Zacks Rank of #2 (Buy).